it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done...
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid... 0 comments ..